

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1.-48. (Canceled)

49. (Currently Amended) A method for screening for a molecule that binds either to ~~a the protein complex of Claim 46 or to any of its protein components, preferably to comprising:~~

- (a) ~~"HDAC1" (SEQ ID No:10); and~~
- (b) ~~"SWI/SNF COMPLEX 60 KDA SUBUNIT" (SEQ ID No:15),~~
- (a) ~~"C20orf20" (SEQ ID No:4), a functionally active derivative thereof, a functionally active fragment thereof, a homolog thereof, or a variant of "C20orf20" encoded by a nucleic acid that hybridizes to the "C20orf20" nucleic acid or its complement under low stringency conditions, or to (b)"KIAA1093 (Fragment)" (SEQ ID No:11), a functionally active derivative thereof, a functionally active fragment thereof, a homolog thereof, or a variant of "KIAA1093 (Fragment)" encoded by a nucleic acid that hybridizes to the "KIAA1093 (Fragment)" nucleic acid or its complement under low stringency conditions, wherein the low stringency conditions comprise (a) hybridization in a buffer comprising about 35% formamide, about 5X SSC, about 50 mM Tris HCl (about pH 7.5), about 5 mM EDTA, about 0.02% PVP, about 0.02% Ficoll, about 0.2% BSA, about 100 µg/ml denatured salmon sperm DNA, and about 10% (wt/vol) dextran sulfate for about 18 to about 20 hours at about 40 Celsius, (b) washing in a buffer consisting of about 2X SSC, about 25 mM Tris HCl (about pH 7.4), about 5 mM EDTA, and about 0.1 % SDS for about 1.5 hours at about 55~~

Celsius, and (e) washing in a buffer consisting of about 2X SSC, about 25 mM Tris-HCl (about pH 7.4), about 5 mM EDTA, and about 0.1% SDS for about 1.5 hours at about 60 Celsius;

the method comprising the steps of:

- (a) exposing the complex ~~or protein component~~, or a cell or organism containing the complex ~~or protein component~~, to one or more candidate molecules; and
- (b) determining whether the one or more candidate molecules ~~is are~~ bound to the complex ~~or protein component~~.

50. **(Currently Amended)** The method of claim 49, wherein the method is for screening for a molecule that modulates directly or indirectly the function, activity, composition, or formation of the complex ~~or protein component~~.

51. **(Currently Amended)** The method of claim 49, wherein the determining step comprises:

- (a) isolating ~~from the cell or organism~~ the complex from the cell or organism ~~or protein component~~ to produce the isolated complex or protein component;
- (b) contacting the isolated complex ~~in the presence or absence of a candidate molecule~~ with a substrate of the complex in the presence or absence of a candidate molecule ~~or protein component~~; and
- (c) determining whether the processing of the substrate is modified in the presence of the candidate molecule.

52. **(Currently Amended)** The method of claim 49, wherein the method is a ~~method of for~~ screening for a drug useful in treating or preventing ~~for treatment or prevention~~ of a disease or disorder such as neurodegenerative diseases such as Alzheimer's disease.

53. **(Currently Amended)** The method of claim 50, wherein the method is for screening of a molecule that modulates the apoptotic activity of the complex ~~or the influence of the protein on the apoptotic activity of the complex.~~

54. **(Previously Presented)** The method of claim 50, further comprising mixing the identified molecule with a pharmaceutically acceptable carrier.

55-56. **(Canceled)**